Oxford Immunotec Global PLC

Oxford Immunotec Global — Investor Presentation (January 2019)

19 slides from Oxford Immunotec Global's investor presentation, Jan 7, 2019

  1. Slide 1: Oxford Immunotec

    Slide 1: Oxford Immunotec

    888 Oxford 606|mmunotec

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward: Looking : Certain information contained in this presentation constitutes forward-looking statements, including those related to anticipated plans and objectives, future performance and revenues, financial condition, prospects, growth, strategies, expectations and objectives of management. F

  3. Slide 3: Locations: Boston, Oxford, Shanghai, Tokyo

    Slide 3: Locations: Boston, Oxford, Shanghai, Tokyo

    aa Boston, MA Oxford, UK US hescavarters ‘Shanghai, China : ‘China marist c Tepan conmereal operations so Oxtord US headauarters * US supply cham operations SUR ODL mb

  4. Slide 4: Growth, Focus, Profitability, Optionality

    Slide 4: Growth, Focus, Profitability, Optionality

    Growth Focus Profitability Optionality Exploit the large, growing and underserved market for Tuberculosis (TB) screening Dramatically simplified operations as a pure-play products company focused on TB Materially improved top- and bottom-line profitability Markedly stronger balance sheet

  5. Slide 5: Tuberculosis: The World's Deadliest Infection

    Slide 5: Tuberculosis: The World's Deadliest Infection

    Tuberculosis: The World’s Deadliest Infection 1 0 5 000,000 Top 10 cause of death globally new cases 1,600,000 “tomsa‘singte infectious agent deaths See: Gta Teens Aap 2018 Gene: is Hanth Crganzaton (WMO) 2018 5

  6. Slide 6: Tuberculosis Control Relies on Screening for Latent TB

    Slide 6: Tuberculosis Control Relies on Screening for Latent TB

    Tuberculosis Control Relies on Screenin for Latent TB “Ending the tuberculosis epidemic will require the elimination of this [reservoir] of infection” - World Health Organization, The End TB Strategy + 1.7 billion people are estimated to have a latent . 2 TB infection 4 5 2 + Individuals with Latent

  7. Slide 7: 50M+ LTBI screening tests performed each year

    Slide 7: 50M+ LTBI screening tests performed each year

    50M+ Latent TB Infection (LTBI) screening tests performed each year UN set aggressive goal for rapid scale up of testing, to get >30 million people on preventative treatment by 2022 ) ‘agsars fr Maris: Gel Coan ans Matt tnt Cava WHO 2998 ‘Set sesenny envion 99 Panel esate st aghavemaving ote See! ‘s

  8. Slide 8: Limitations of the skin test for TB

    Slide 8: Limitations of the skin test for TB

    est for TB “This method has been inclinical use for morethan 90 years. Unfortunately, its applicationis problematic due to the frequency of false-positive and false-negative skin reactions.” - World Health Organization, Diagnostics for Tuberculosis Main Limitations + Low sensitivity, especially in i

  9. Slide 9: Our solution: T-SPOT.TB

    Slide 9: Our solution: T-SPOT.TB

    + Our solution: T-SPOT®.7B © Blood test based on immunology; generically referred to as an interferon-gamma release assay o One of two recommended alternatives to TST © Superior sensitivity cited in recent guideline updates and publications * IGRAs have several advantages over the TST © Higher speci

  10. Slide 10: T-SPOT.TB regulatory and reimbursement milestones

    Slide 10: T-SPOT.TB regulatory and reimbursement milestones

    | i SERERERRES roa! sous aus noonnnnmmmnell sent Ree BREA EREAZAZAPAZA Ser: Oxo inmates company one (CE mark (EU approval), 1* EU guideline, US FDA approval 2010 | COC guidelines issued in US: Chinese SFDA approval 2011 | CPT code & US Medicare reimbursement established ‘2012 | Japanese MHLW approva

  11. Slide 11: Potential market opportunity exceeds 50M+ tests annually

    Slide 11: Potential market opportunity exceeds 50M+ tests annually

    Yet, Adoptior Potential market opportunity ° exceeds: 50M+ tests annually ~20 - 25% Market Share ec: Cnet nme anys Guidelines becoming ever more supportive of conversion e AAP guidelines on LTBI screening, June 2018 — _IGRAs to be used even in children as young as 2 years old e WHO Essential Diagnos

  12. Slide 12: The Largest Screened Populations and US Market by Segment

    Slide 12: The Largest Screened Populations and US Market by Segment

    : The Largest S Principal Screened Populations ate, = SPOT: 2 Loree; es! sion 7 Reacts ‘Sowc:Oxtrsinemaaas eave Tay, Conecora Fasten nen Cae Homes, ad oer 12 US Market by Segment Market Segment by Segment Size Testing Location (Tests/Year) Hospitals 7.0M | Public & Student Health 1.5M Physicians’ Of

  13. Slide 13: Quest Deal Broadens US Market Access for T-SPOT.TB

    Slide 13: Quest Deal Broadens US Market Access for T-SPOT.TB

    Quest Deal Broadens US Market Access for T-SPOT.7TB By leveraging Quest's reach and capabilities, US market access to T-SPOT.TB will be immediately broadened: 7 Enables unparalleled access to the large physician office market segment 4 Helps remove barriers to adoption '# Gaining an additional voice

  14. Slide 14: Outside the US: Demand for TB Screening

    Slide 14: Outside the US: Demand for TB Screening

    Outside the | id for TB Sc + Already strong uptake of IGRAs in developed markets co Wehave a strong business in Europe and in Japan where we are the market leader + Growing market as countries expand TB screening / ij, © Significant new programs over past years in UK, Korea, China | & 2 2018 WHO lat

  15. Slide 15: T-Cell Select enables full automation of T-SPOT.TB

    Slide 15: T-Cell Select enables full automation of T-SPOT.TB

    T-Cell Se/ect enables full automation of T-SPOT.7B, providing unrivaled sample stability and simplicity of blood collection 54-hour storage at room temperature T-Cell i Sample Stability Benefits: o Longest sample stability o Most flexible logistics o Expands laboratory reach © Enables sample batchin

  16. Slide 16: Acquire products/companies in TB

    Slide 16: Acquire products/companies in TB

    TB Acquire productsicompanies in the TB space to leverage and expand our competitive position Channel Leverage our global ‘manufacturing, regulatory and ‘commercial channel through acquisition of entities that can benefit from this

  17. Slide 17: Financial Profile

    Slide 17: Financial Profile

    Financial Profile * Strong momentum in TB business GROSS MARGINS* o Recurring revenue allows us to focus sales teams ee primarily on driving growth o Record volumes in Q3 ‘2018 © Broad-based growth across US, Asia, and Europe & ROW * Significantly enhanced gross margin profile 60% © ~70% gross margi

  18. Slide 18: Key Priorities for 2019

    Slide 18: Key Priorities for 2019

    Key Priorities for 2019 Growth & Focus Profitability Optionality Accelerate revenue growth through strategic collaboration with Quest Diagnostics, which significantly increases the reach and competitiveness of T-SPOT. TBin the largest market for TB screening (the US) Grow commercial channels outside

  19. Slide 19: Summary & Key Investment Highlights

    Slide 19: Summary & Key Investment Highlights

    ummary & Key Investment Highlights + Leadership position in new class of testing for world’s deadliest infectious disease Very large, growing, underserved market Differentiated, industry-leading immunology technology Diversified, recurring revenue streams Strong revenue growth Strong gross margins P

Source: SEC EDGAR · 8-K filed Jan 7, 2019

More decks from Oxford Immunotec Global PLC